Yuming Wang
Southwest Hospital, China
Title: Efficacy comparison among three Pegylated interferon alfa monotherapies based on 24 week response in HBeAg-positive CHB patients
Biography
Biography: Yuming Wang
Abstract
40 kD PEG IFN α-2a and 12kD PEG IFN α-2b have demonstrated effective immune control and resulted in better response in HBeAg positive CHB patients compared to nucleos(t)ide drugs (NUCs), e.g. HBeAg seroconversion and HBsAg loss. [1,2]However, efficacy of another PEG IFN α, i.e. 40kD PEG IFN α-2b, has not been reported yet.
Aim
This study aimed to compare efficacy among three PEG IFNα monotherapies in antiviral treatment-naïve HBeAg-positive CHB patients.
Material and Methods
Total 117 antiviral treatment-naïve HBeAg-positive CHB patients were enrolled. Subjects were randomly to receive 24 weeks of 40kD PEG IFN-α-2a (180 μg/week, Group A, n=41), 12kD PEG IFN α-2b (80μg/week, Group B, n=41), or 40kD PEG IFN-α-2b (180 μg/week, Group C, n=52) monotherapy. Primary endpoint was defined as satisfactory response (virological and biochemical response, plus anti-HBe seroconversion) at week 24. Secondary endpoints included ideal response (HBsAg loss) and HBsAg decline at week 24. All patients were further followed up during treatment.
Results
There were no signiï¬cant differences in sex, age, HBV genotype and ALT level among three monotherapy groups (P>0.05). After treatment of 24 weeks, satisfactory response rate in 40kD PEG IFN-α-2b group (30.77%,16/52) was higher than Group A (17.07%, 7/41, P=0.1285) and Group B (12.20%,5/41, P=0.0634), although with no statistically significant difference (P>0.05). Ideal response rates in 40kD PEG IFN-α-2b group (17.31%,9/52) was slightly higher than Group A (7.32%,3/41, P=0.1536)and Group B (4.87%,2/41, P=0.0653) . Partial response rates as HBsAg level decline from baseline were a bit higher in 40kD PEG IFN-α-2b group compared to 40kD PEG IFN-α-2a group (P>0.05)(Table).
Conclusion
Compared to 40kD PEG IFN-α-2a and 12kD PEG IFN α-2b monotherapies, 40kD PEG IFN-α-2b monotherapy showed trends for better efficacy for antiviral treatment-naïve HBeAg positive patients at week 24. Meanwhile, 40kD PEG IFN-α-2b is at a much cheaper price, which exerts a better cost effects.
Table
Table. Response after treatment of 12 weeks
|
HBsAg decline from baseline |
Group A 40kD PEG IFN-α-2a (n=41) |
Group B 12kD PEG IFN α-2b (n=41) |
Group C 40kD PEG IFN-α-2b (n=52) |
P |
|
1lg-2lg HBsAg decline from baseline |
7(17.1%) |
_ |
8(15.4%) |
0.8265 |
|
2lg-3lg HBsAg decline from baseline |
12 (29.2%) |
_ |
13(25.0%) |
0.6452 |
|
≥3lg HBsAg decline from baseline |
18(43.9%) |
_ |
29(55.8%) |
0.2558 |